Drug Trial Radar · NCT06893016
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Last checked: Nov 19, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
640
Planned (sponsor's estimate)
Start
Jun 15, 2025
Primary completion
Jun 15, 2026
Study completion Sep 15, 2026
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
Conditions
- Obesity
Interventions
RAY1225Drug
RAY1225 will be administered SC
PlaceboDrug
Placebo will be administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body Weight at Week 52Time frame: Baseline and Week 52
- Number of Participants who Achieved a ≥ 5% Reduction in Body Weight from Baseline at Week 52Time frame: Baseline and Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.